{"public_id":"cl_0b07084d6a0829141c5be483a144bce8","status":"active","superseded_by_public_id":null,"corpus_id":86816391,"text":"A mean of 7.7 (±1.2) injections and 4.4 (±1.6) clinic visits in the first year and 4.4 (±1.9) injections and 4.3 (±1.3) clinical visits per year thereafter were required.","confidence":0.95,"paper":{"corpus_id":86816391,"title":"Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a \"Treat-and-Extend\" Regimen.","url":"https://sah.borca.ai/papers/86816391"},"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_a252f3acea26b2cb3e59b98cac812e05","name":"injections per year","description":"Mean number of aflibercept injections administered per year during the treat-and-extend regimen.","types":["treatment burden metric"],"url":"https://sah.borca.ai/concepts/co_a252f3acea26b2cb3e59b98cac812e05"},{"public_id":"co_b66f4d5f43bd2055ce5c584f16f8a13a","name":"clinic visits per year","description":"Mean number of clinical visits per year for monitoring disease activity.","types":["treatment burden metric"],"url":"https://sah.borca.ai/concepts/co_b66f4d5f43bd2055ce5c584f16f8a13a"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_0b07084d6a0829141c5be483a144bce8"}